Laser Design CyberGage®360, Automated 3D Scanning & Inspection System Adopted by Proto Labs in their State-of-the-Art Metrology Lab
Laser Design, Inc. , a subsidiary of CyberOptics (NASDAQ:CYBE), and premier provider of ultra-precise 3D scanning systems and services, announces the adoption of the CyberGage360 3D Scanning and Inspection system by Proto Labs , the world’s fastest digital manufacturing source for custom prototypes and low-volume production parts providing unprecedented speed-to-market value for designers and engineers.
“At Proto Labs, we strive to challenge the traditional rules of manufacturing in order to deliver custom manufactured components at unprecedented speeds,” said Dylan Lundberg, Senior Manufacturing Engineer of Protoworks, Proto Labs’ R&D lab. “Everything we do revolves around reducing our customers’ time to market and we do that by digitalizing the entire manufacturing process. From our front-end services to our proprietary processes on the manufacturing floor, you will find three consistent objectives: it’s fast, it’s easy, and it maintains the digital thread. The CyberGage360 comfortably satisfies all three of these needs. It is the synergistic solution we were looking for to be at the focal point of our lab and future metrology offerings.”
“3D scanning of complex parts now simply involves opening a door, putting your part in, and pressing a button. The result is a highly-precise 3D scan with a full 3D inspection report in just a few minutes,” said C. Martin Schuster, President and CEO of Laser Design. “We are delighted that Proto Labs, an on-demand manufacturing powerhouse helping shape Industry 4.0, has adopted the CyberGage360 systems in their state-of-the-art metrology lab.”
“We are very excited to add digital inspection reports to our service offerings,” said Proto Labs President and CEO, Vicki Holt. “The addition of CyberGage360 scanning and inspection systems is a natural extension of our technology-enabled manufacturing approach as we aim to provide product developers and engineers with a total solution to streamline path to market.”
CyberGage360 greatly facilitates Quality Assurance by allowing anyone to be an inspector of in-process and incoming/outgoing parts on the manufacturing floor or in the metrology lab, lowering customers’ cost of quality and speeding products to market. With little training, anyone can check parts for any deviation from CAD or check critical features. Designed for use in general purpose metrology, the CyberGage360 has a range of potential applications for consumer electronics, medical, automotive, aerospace and other verticals, where high accuracy and high speed throughput are vital.
Incorporating CyberOptics’ proprietary 3D Multi-Reflection Suppression (MRS) technology, the automated CyberGage360 brings significantly greater accuracy and scanning speeds to the industrial parts inspection and reverse engineering markets.
About Laser Design, Inc.
Laser Design, Inc., a subsidiary of CyberOptics (NASDAQ: CYBE), is the premiere provider of ultra-precise 3D scanning systems and 3D measurement services. Laser Design has helped customers successfully complete their most complex inspection, analysis, and reverse engineering projects for more than 30 years. Its experienced metrologists and engineers know that today more than ever, accuracy, speed and automation give manufacturers the competitive advantage.
CyberOptics Corporation (NASDAQ: CYBE) is a leading global developer and manufacturer of high precision sensing technology solutions. CyberOptics sensors are being used in general purpose metrology and 3D scanning, surface mount technology (SMT) and semiconductor markets to significantly improve yields and productivity. By leveraging its leading edge technologies, the company has strategically established itself as a global leader in high precision 3D sensors, allowing CyberOptics to further increase its penetration of its key vertical markets. Headquartered in Minneapolis, Minnesota, CyberOptics conducts worldwide operations through its facilities in North America, Asia and Europe.
Statements regarding the Company’s anticipated performance are forward-looking and therefore involve risks and uncertainties, including but not limited to: market conditions in the global SMT and semiconductor capital equipment industries; the timing of orders and shipments of our products, particularly our 3D MRS-enabled AOI systems; increasing price competition and price pressure on our product sales, particularly our SMT systems; the level of orders from our OEM customers; the availability of parts required to meet customer orders; unanticipated product development challenges; the effect of world events on our sales, the majority of which are from foreign customers; rapid changes in technology in the electronics markets; product introductions and pricing by our competitors; the success of our 3D technology initiatives; the success of CyberGage360; and other factors set forth in the Company’s filings with the Securities and Exchange Commission.
All names are trademarks of their respective companies.
Carla Furanna, 952-820-5837
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Skrive dig op her og du vil løbende modtage pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Business Wire
ASTRAZENECA10.12.2017 23:47 | pressemeddelelse
AstraZeneca’s Calquence (acalabrutinib) Shows Potential in Chronic Lymphocytic Leukaemia Trials
NJ-CELGENE/BLUEBIRD-BIO10.12.2017 16:32 | pressemeddelelse
Celgene Corporation and bluebird bio Announce Updated Results from Ongoing Multicenter Phase 1 Study of bb2121 Anti-BCMA CAR T Cell Therapy in Patients with Late Stage Relapsed/Refractory Multiple Myeloma at ASH Annual Meeting
GA-GILEAD-SCIENCES/KITE10.12.2017 16:32 | pressemeddelelse
Kite Announces Long-Term Data From Pivotal ZUMA-1 Study of Yescarta™ (Axicabtagene Ciloleucel) in Patients With Refractory Large B-cell Lymphoma
MA-TAKEDA/SEATTLE10.12.2017 14:02 | pressemeddelelse
Takeda and Seattle Genetics to Present Positive Data from Phase 3 ECHELON-1 Clinical Trial Evaluating ADCETRIS® (brentuximab vedotin) in Frontline Advanced Hodgkin Lymphoma
ASTRAZENECA9.12.2017 19:02 | pressemeddelelse
AstraZeneca’s Calquence (acalabrutinib) Demonstrates Activity in Relapsed or Refractory Mantle Cell Lymphoma Trial
JANSSEN9.12.2017 18:21 | pressemeddelelse
Sustained Benefit in Patients with Relapsed/Refractory Mantle Cell Lymphoma Demonstrated by 3.5 Year Follow-up Data of Imbruvica®▼(ibrutinib)
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum